Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study
Inflammatory breast cancer (IBC) is a rare entity with a poor prognosis. We analysed the survival outcomes of patients with nonmetastatic IBC and the prognostic value of tumour or nodal responses to assess their individual prognostic impact across IBC subtypes. This retrospective multicentre study i...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/16/3928 |
| _version_ | 1797432372797374464 |
|---|---|
| author | Maximilien Rogé Julia Salleron Youlia Kirova Marin Guigo Axel Cailleteau Christelle Levy Marianne Leheurteur Rafik Nebbache Eleonor Rivin Del Campo Ioana Lazarescu Stéphanie Servagi Maud Aumont Juliette Thariat Sébastien Thureau |
| author_facet | Maximilien Rogé Julia Salleron Youlia Kirova Marin Guigo Axel Cailleteau Christelle Levy Marianne Leheurteur Rafik Nebbache Eleonor Rivin Del Campo Ioana Lazarescu Stéphanie Servagi Maud Aumont Juliette Thariat Sébastien Thureau |
| author_sort | Maximilien Rogé |
| collection | DOAJ |
| description | Inflammatory breast cancer (IBC) is a rare entity with a poor prognosis. We analysed the survival outcomes of patients with nonmetastatic IBC and the prognostic value of tumour or nodal responses to assess their individual prognostic impact across IBC subtypes. This retrospective multicentre study included patients diagnosed with IBC between 2010 and 2017 to account for advances in neoadjuvant systemic therapies and modern radiotherapy at seven oncology centres in France. Three hundred and seventeen patients were included and analysed. After a median follow-up of 52 months, the 5-year DFS was lower for triple-negative (TN) (50.1% vs. 63.6%; <i>p</i> < 0.0001). After multivariate analyses, incomplete nodal response was the only significant prognostic factor in the triple-negative group (HR:6.06). The poor prognosis of TN-IBC was reversed in the case of nodal response after neoadjuvant chemotherapy. Breast response does not appear to be a decisive prognostic factor in patients with TN-IBC compared to lymph node response. Despite improvements in neoadjuvant treatments, IBC remains associated with a poor prognosis. In TN-IBC patients, lack of pathological complete node response was associated with poorer survival than any other group. Treatment intensification strategies are worth investigating. |
| first_indexed | 2024-03-09T09:59:35Z |
| format | Article |
| id | doaj.art-84e8d4c4b4fc47ff90d3a22e9085a205 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T09:59:35Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-84e8d4c4b4fc47ff90d3a22e9085a2052023-12-01T23:32:15ZengMDPI AGCancers2072-66942022-08-011416392810.3390/cancers14163928Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-StudyMaximilien Rogé0Julia Salleron1Youlia Kirova2Marin Guigo3Axel Cailleteau4Christelle Levy5Marianne Leheurteur6Rafik Nebbache7Eleonor Rivin Del Campo8Ioana Lazarescu9Stéphanie Servagi10Maud Aumont11Juliette Thariat12Sébastien Thureau13Department of Radiation Oncology, Henri Becquerel Cancer Center, 76000 Rouen, FranceDepartment of Biostatistics, Institut de Cancérologie de Lorraine, 54500 Vandœuvre-Lès-Nancy, FranceDepartment of Radiation Oncology, Institut Curie, 75005 Paris, FranceDepartment of Radiation Oncology, Centre François Baclesse, 14000 Caen, FranceDepartment of Radiation Oncology, Institut de Cancérologie de l’Ouest, Nantes, 44300 Saint-Herblain, FranceDepartment of Medical Oncology, Centre François Baclesse, 14000 Caen, FranceDepartment of Medical Oncology, Centre Henri Becquerel, 76000 Rouen, FranceDepartment of Radiation Oncology, Tenon University Hospital, Sorbonne University, 75020 Paris, FranceDepartment of Radiation Oncology, Tenon University Hospital, Sorbonne University, 75020 Paris, FranceDepartment of Radiation Oncology, Centre de la Baie, 50300 Avranches, FranceDepartment of Radiation Oncology, Institut Jean Godinot, 51100 Reims, FranceDepartment of Radiation Oncology, Institut de Cancérologie de l’Ouest, Nantes, 44300 Saint-Herblain, FranceDepartment of Radiation Oncology, Centre François Baclesse, 14000 Caen, FranceDepartment of Radiation Oncology and Nuclear Medicine, Henri Becquerel Cancer Center, and QuantIF LITIS, 76000 Rouen, FranceInflammatory breast cancer (IBC) is a rare entity with a poor prognosis. We analysed the survival outcomes of patients with nonmetastatic IBC and the prognostic value of tumour or nodal responses to assess their individual prognostic impact across IBC subtypes. This retrospective multicentre study included patients diagnosed with IBC between 2010 and 2017 to account for advances in neoadjuvant systemic therapies and modern radiotherapy at seven oncology centres in France. Three hundred and seventeen patients were included and analysed. After a median follow-up of 52 months, the 5-year DFS was lower for triple-negative (TN) (50.1% vs. 63.6%; <i>p</i> < 0.0001). After multivariate analyses, incomplete nodal response was the only significant prognostic factor in the triple-negative group (HR:6.06). The poor prognosis of TN-IBC was reversed in the case of nodal response after neoadjuvant chemotherapy. Breast response does not appear to be a decisive prognostic factor in patients with TN-IBC compared to lymph node response. Despite improvements in neoadjuvant treatments, IBC remains associated with a poor prognosis. In TN-IBC patients, lack of pathological complete node response was associated with poorer survival than any other group. Treatment intensification strategies are worth investigating.https://www.mdpi.com/2072-6694/14/16/3928inflammatory breast cancertriple-negativeneoadjuvant chemotherapyradiotherapypathological responsesurvival |
| spellingShingle | Maximilien Rogé Julia Salleron Youlia Kirova Marin Guigo Axel Cailleteau Christelle Levy Marianne Leheurteur Rafik Nebbache Eleonor Rivin Del Campo Ioana Lazarescu Stéphanie Servagi Maud Aumont Juliette Thariat Sébastien Thureau Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study Cancers inflammatory breast cancer triple-negative neoadjuvant chemotherapy radiotherapy pathological response survival |
| title | Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study |
| title_full | Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study |
| title_fullStr | Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study |
| title_full_unstemmed | Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study |
| title_short | Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study |
| title_sort | different prognostic values of tumour and nodal response to neoadjuvant chemotherapy depending on subtypes of inflammatory breast cancer a 317 patient study |
| topic | inflammatory breast cancer triple-negative neoadjuvant chemotherapy radiotherapy pathological response survival |
| url | https://www.mdpi.com/2072-6694/14/16/3928 |
| work_keys_str_mv | AT maximilienroge differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT juliasalleron differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT youliakirova differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT maringuigo differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT axelcailleteau differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT christellelevy differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT marianneleheurteur differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT rafiknebbache differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT eleonorrivindelcampo differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT ioanalazarescu differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT stephanieservagi differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT maudaumont differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT juliettethariat differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy AT sebastienthureau differentprognosticvaluesoftumourandnodalresponsetoneoadjuvantchemotherapydependingonsubtypesofinflammatorybreastcancera317patientstudy |